← Who reports today · Health Care
BSX · Q2 2026
Archived report (Q2 2026). Latest deep dive →
The quarter in brief
Revenue grew 7.5% y/y to $5.44B, operating margin 21.6% vs 16.2%, net income $907M (+13.8% y/y).
Net income (loss) attributable to Boston Scientific common stockholders
$907M
up 13.8% y/y
Net sales
$5,442M
up 7.5% y/y
Operating income (loss)
$1,178M
up 43.8% y/y
Gross profit
$3,848M
up 12.4% y/y
All figures in $M.
| Line item | Amount and change |
|---|---|
| Net sales | $5,442 · +7.5% |
| Cost of products sold | $1,594 · −2.6% |
| Gross profit | $3,848 · +12.4% · 70.7% margin |
| Selling, general and administrative expenses | $1,803 · +5.1% |
| Research and development expenses | $554 · +5.3% |
| Royalty expense | $12 · −14.3% |
| Amortization expense | $233 · +3.6% |
| Contingent consideration net expense (benefit) | $16 · +220% |
| Restructuring net charges | $8 · −90.4% |
| Litigation-related net charges | $76 · vs $0 |
| Operating income (loss) | $1,178 · +43.8% · 21.6% margin |
| Interest expense | $96 · +6.7% |
| Other, net | $23 · vs $213 |
| Income (loss) before income taxes | $1,060 · +12.6% |
| Income tax expense (benefit) | $155 · +6.2% · 14.6% effective rate |
| Net income (loss) attributable to noncontrolling interests | $2 · +0.0% |
| Net income (loss) attributable to Boston Scientific common stockholders | $907 · +13.8% · $0.61/sh · 16.7% margin |
Verdict: revenue grew 7.5% y/y to $5.44B, operating margin 21.6% vs 16.2%, net income $907M (+13.8% y/y).
Source and notation
Source: Boston Scientific press release, 8-K EX-99.1 of 07/29/2026 (SEC EDGAR). Every figure was matched against the income statement in the release and checked against SEC XBRL.
Open as an image: BSX, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “BSX Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/bsx/q2-2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/bsx/q2-2026"><img src="https://whoreportstoday.com/t/bsx/q2-2026/sankey.png" alt="BSX Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/bsx/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/bsx/q2-2026/sankey.png
<a href="https://whoreportstoday.com/t/bsx/q2-2026">BSX Q2 2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Gross margin was 70.7% vs 67.7% a year earlier.
- Operating income was $1.18B, a 21.6% margin vs 16.2% a year earlier.
- The effective tax rate was 14.6% vs 15.5% a year earlier.
- Diluted EPS was $0.61 vs $0.53 a year earlier.
What distorts the picture in this report and what to watch beyond the headlines.
BSX — a developer, manufacturer and marketer of medical devices for less-invasive procedures, used by physicians in cardiology, electrophysiology, vascular care, endoscopy, urology, neuromodulation and other interventional specialties.
It reports two segments: MedSurg and Cardiovascular. · Source: annual report (Form 10-K, SEC)
More reports: CAH · Q4 FY2026 · CI · Q2 2026 · CNC · Q3 2026 · COO · Q3 FY2026 · COR · Q3 FY2026 · CRL · Q2 2026 · CVS · Q2 2026 · DGX · Q3 2026 · DHR · Q3 2026 · DVA · Q3 2026 · all reports